460367-82-2 Usage
General Description
"tert-Butyl 4-ethoxypiperidine-1-carboxylate" is an organic chemical compound with the molecular formula C12H23NO3. It is categorized as a piperidine and ester compound. Piperidines are part of a broader class of organic compounds containing a piperidine ring, which is a heterocyclic ring structure made up of five carbon atoms and a nitrogen atom. Ester compounds are derived from carboxylic acids and an alcohol. "tert-Butyl 4-ethoxypiperidine-1-carboxylate" is used as an intermediate in the synthesis of various pharmaceutical drugs, and it is typically in the form of a clear, colorless liquid. Its safety, potential hazards, and proper handling methods should be well understood before using it.
Check Digit Verification of cas no
The CAS Registry Mumber 460367-82-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,6,0,3,6 and 7 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 460367-82:
(8*4)+(7*6)+(6*0)+(5*3)+(4*6)+(3*7)+(2*8)+(1*2)=152
152 % 10 = 2
So 460367-82-2 is a valid CAS Registry Number.
460367-82-2Relevant articles and documents
AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
-
Paragraph 0508; 0509, (2019/06/07)
An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.
CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS
-
Page/Page column 79, (2010/11/27)
Chroman derivatives according to Formula (I) below: wherein R1, R2, R3 ,and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical .compositions containing a
